Micardisplus (Hydrochlorothiazide, Telmisartan)

Micardisplus is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

• Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent stroke and heart attack.
• Secondary hypertension due to renal disease: assists in controlling pressure when other causes are present.
• Hypertension requiring combination therapy: provides both ARB and diuretic effects in a single tablet.

• Telmisartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, promoting diuresis and reducing plasma volume. The combined actions lower systemic vascular resistance and cardiac preload, resulting in sustained blood‑pressure reduction.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate tension‑type pain.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: particularly low potassium levels.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Acute kidney injury: sudden decline in renal function.
• Significant hypotension: marked drop in blood pressure causing faintness.
• Hyperkalemia: elevated potassium that can affect heart rhythm.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider the following precautions:

• Renal function: assess creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor serum potassium and sodium regularly.
• Pregnancy: contraindicated (Category D) due to fetal risk.
• Concomitant ACE inhibitor or ARB therapy: avoid combined use to reduce renal injury risk.
• Severe hepatic impairment: use with caution or avoid.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Micardisplus may interact with several medicines; careful review is required.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal dysfunction.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• Lithium: may raise lithium concentrations, leading to toxicity.
• NSAIDs: can blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: combined use may cause renal impairment.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering, monitor for excessive hypotension.
• Calcium channel blockers: may enhance hypotensive response.
• Antidiabetic agents: blood‑glucose levels may fall, requiring dose adjustment.